Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone dose-escalation study in advanced ovarian, fallopian tube, or primary peritoneal cancer
2005-004913-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patupilone in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Novartis. Primary endpoints: Overall response rate, Overall response rate by RECIST and 1 more. Started Nov 2005; status: completed.
02
Drugs
patupilone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-004913-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004913-14.